INCY

Incyte Corporation

Price

$122.52

return (12m)

42.05%

p/e

15.86

p/bv

4.03

DIVIDEND YIELD

0.00%

INCY price

Incyte

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment INCY

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.91%

3 months

12.89%

1 year

42.05%

2 years

94.08%

5 years

69.11%

10 years

54.68%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals INCY

Valuation

P/E

15.86

Sector -3.77

Industry -3.77

P/BV

4.03

Sector 2.17

Industry 2.17

P/Revenue (PSR)

4.39

Sector 2.19

Industry 2.19

EV/EBITDA

27.02

Sector -220.57

Industry -220.57

EV/EBIT

27.97

Sector -47.40

Industry -47.40

P/EBITDA

12.36

Sector -21.39

Industry -21.39

P/EBIT

12.98

Sector -31.64

Industry -31.64

P/Total Assets

3.25

Sector 1.27

Industry 1.27

P/Net Current Assets

5.68

Sector -10.98

Industry -10.98

P/Working Capital

5.42

Sector -189.70

Industry -189.70

EPS

8.05

Sector -1.77

Industry -1.77

BVPS

31.66

Sector 2.05

Industry 2.05

Efficiency

Gross Margin

92.62%

Sector 40.99%

Industry 40.99%

EBITDA Margin

46.51%

Sector -17,787.66%

Industry -17,787.66%

EBIT Margin

44.93%

Sector -4,203,887.23%

Industry -4,203,887.23%

Operating Margin

30.56%

Sector -34.94%

Industry -34.94%

Net Profit Margins

27.71%

Sector -35.70%

Industry -35.70%

Asset Turnover

0.21

Sector 0.03

Industry 0.03

Profitability

ROE

25.41%

Sector -56.49%

Industry -56.49%

ROA

20.48%

Sector -59.79%

Industry -59.79%

ROIC

77.32%

Sector -2,350.98%

Industry -2,350.98%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

4.59

Sector 2.92

Industry 2.92

Net Debt / EBITDA

-5.83

Sector -14,656,762.33

Industry -14,656,762.33

Net Debt / EBIT

-6.03

Sector -8.32

Industry -8.32

Net Debt / Equity

-0.71

Sector -32,504.62

Industry -32,504.62

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.81

Sector 0.46

Industry 0.46

Liabilities/Assets

0.19

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

14.28%

Sector -

Industry -

5Y Earnings CAGR

11.19%

Sector -

Industry -

Fundamentals INCY

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Incyte ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$122.52

Fair Value

$75.73

Upside Return potential.

-38.19%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
INCY Incyte Corporation	$122.52	42.05%	0.00%	15.86	4.03	25.41%	27.71%
JNJ Johnson & Johnson	$266.30	54.92%	1.90%	31.48	7.79	24.76%	21.48%
PFE Pfizer Inc.	$27.55	20.01%	6.01%	37.36	1.91	5.11%	6.86%
ABBV AbbVie Inc.	$257.60	25.60%	2.66%	72.11	-76.75	-106.44%	9.81%
NVO Novo Nordisk A/S	$42.96	-16.95%	3.97%	11.43	6.07	53.11%	35.32%
MRK Merck & Co. Inc.	$144.93	79.22%	2.24%	116.76	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$158.97	-0.30%	1.98%	19.30	4.97	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$63.37	40.78%	3.75%	14.74	6.13	41.55%	18.85%
ZTS Zoetis Inc.	$72.29	-50.69%	2.76%	11.95	10.04	84.02%	27.77%
AMGN Amgen Inc.	$379.89	41.30%	2.25%	26.93	20.14	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.06	38.54%	0.44%	19.82	2.71	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$107.43	41.73%	0.00%	31.19	89.88	288.13%	24.86%
MCK McKesson Corporation	$879.50	25.17%	0.36%	20.52	-28.15	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$514.50	32.42%	0.00%	31.75	6.91	21.76%	35.00%
CAH Cardinal Health Inc.	$233.17	58.18%	0.83%	37.62	-21.79	-57.93%	0.62%
ARGX argenx SE	$992.94	30.16%	0.00%	3.11	3.48	112.18%	44.41%
HRMY Harmony Biosciences Holdings Inc.	$41.50	24.96%	0.00%	13.47	2.44	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

INCY Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Incyte

Incyte Corporation

Average Investor10 user rating

4.0 (6 people)

United States

35 years

Founded: 1991

1993

Time since IPO - 33 years

1.773

Employees

Incyte Corporation (United States) is listed on the Nasdaq and has a market capitalization of $25.57 billion, with shareholders equity totaling $6.34 billion.

The company employs approximately 1.773 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Incyte Corporation reported $5.82 billion in revenue, generating net income of $1.61 billion.

Key financial metrics include a P/E ratio of 15.86, a price-to-book (P/B) ratio of 4.03, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INCY.

Market cap

$25.57 billion

Net worth

$6.34 billion

$6,344,427,000.00

Assets

$7.87 billion

$7,872,647,000.00

Total Shares Outstanding

200.38 million

200,378,000

Average Daily Trading Volume

$1.66 million

$1,658,926.92

Sector

Health Care

Industry

Biotechnology

INCY

revenue by Business Segment Incyte

Revenue by Region Incyte

INCY revenue and profits

Financial Results INCY

DRAG THE FRAME TO SEE MORE DATA

INCY cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$879.50 22,81% (12M)

P/E

20.52

0.36%

ROE

-137.16%

P/BV

-28.15

CAH - Cardinal Health

$233.17 54,88% (12M)

P/E

37.62

0.83%

ROE

-57.93%

P/BV

-21.79

JNJ - Johnson & Johnson

$266.30 52,57% (12M)

P/E

31.48

1.90%

ROE

24.76%

P/BV

7.79

ABBV - AbbVie

$257.60 20,71% (12M)

P/E

72.11

2.66%

ROE

-106.44%

P/BV

-76.75

MRK - Merck & Co.

$144.93 76,86% (12M)

P/E

116.76

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$158.97 1,63% (12M)

P/E

19.30

1.98%

ROE

25.77%

P/BV

4.97

PFE - Pfizer

$27.55 18,61% (12M)

P/E

37.36

6.01%

ROE

5.11%

P/BV

1.91

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$879.50 22,81% (12 M)

P/L

20.52

0.36%

ROE

-137.16%

P/VP

-28.15

CAH - Cardinal Health

$233.17 54,88% (12 M)

P/L

37.62

0.83%

ROE

-57.93%

P/VP

-21.79

JNJ - Johnson & Johnson

$266.30 52,57% (12 M)

P/L

31.48

1.90%

ROE

24.76%

P/VP

7.79

ABBV - AbbVie

$257.60 20,71% (12 M)

P/L

72.11

2.66%

ROE

-106.44%

P/VP

-76.75

MRK - Merck & Co.

$144.93 76,86% (12 M)

P/L

116.76

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$158.97 1,63% (12 M)

P/L

19.30

1.98%

ROE

25.77%

P/VP

4.97

PFE - Pfizer

$27.55 18,61% (12 M)

P/L

37.36

6.01%

ROE

5.11%

P/VP

1.91

Frequently Asked Questions

What is the price of Incyte (INCY) today?

A cotação de Incyte (INCY) hoje está em US$ 122.52, com uma variação de 42.05% em relação ao último ano. A cotação de Incyte (INCY) iniciou o ano negociando na casa dos US$ 98.77 e hoje está em US$ 122.52. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Incyte (INCY) e dados de ações do Ibovespa e mercados internacionais.

Quando Incyte (INCY) paga dividendos?

Incyte (INCY) não distribuiu dividendos no último ano.

Is Incyte (INCY) a good investment?

Atualmente, Incyte (INCY) está cotada a US$ 122.52, com um P/L de 15.86, representando um desvio de 10,277% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 42.05 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 42.05%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Incyte (INCY) stock?

Investir em ações de Incyte (INCY) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Incyte (INCY) yield today?

A rentabilidade de Incyte (INCY) foi de 0.91% no último mês, 42.05% no último ano e 69.11% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Incyte (INCY) hoje, o investimento total seria de US$ 12,252.00, com base na cotação atual de US$ 122.52.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 17,403.97
Em 5 anos: US$ 20,719.36
Em 10 anos: US$ 18,951.39

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

INCY

Incyte Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment INCY

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING INCY WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Incyte

Incyte Corporation

United States

35 years

1993

1.773

PROFIT X PRICE INCY

Financial Results INCY

INCY cash flow

Asset, Revenue and Profit Growth - INCY

INCY balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions